Site-directed Late-stage Diversification of Macrocyclic Nannocystins Facilitating Anticancer SAR and Mode of Action Studies
Overview
Authors
Affiliations
Nannocystins are a family of 21-membered cyclodepsipeptides with excellent anticancer activity. However, their macrocyclic architecture poses a significant challenge to structure modification. Herein, this issue is addressed by leveraging the strategy of post-macrocyclization diversification. In particular, a novel serine-incorporating nannocystin was designed so that its appending hydroxyl group could diversify into a wide variety of side chain analogues. Such effort facilitated not only structure-activity correlation at the subdomain of interest, but also the development of a macrocyclic coumarin-labeled fluorescence probe. Uptake experiments indicated good cell permeability of the probe, and endoplasmic reticulum was identified as its subcellular localization site.
Zhang H, Xie F, Yuan X, Dai X, Tian Y, Sun M Acta Pharmacol Sin. 2024; 45(5):1044-1059.
PMID: 38326625 PMC: 11053100. DOI: 10.1038/s41401-024-01231-w.
Heck Macrocyclization in Forging Non-Natural Large Rings including Macrocyclic Drugs.
Cai J, Sun B, Yu S, Zhang H, Zhang W Int J Mol Sci. 2023; 24(9).
PMID: 37175956 PMC: 10179193. DOI: 10.3390/ijms24098252.
Anticancer Small-Molecule Agents Targeting Eukaryotic Elongation Factor 1A: State of the Art.
Zhang H, Cai J, Yu S, Sun B, Zhang W Int J Mol Sci. 2023; 24(6).
PMID: 36982256 PMC: 10049629. DOI: 10.3390/ijms24065184.